AXIM® Biotechnologies Releases Preprint Manuscript Describing the Development of Company’s Rapid Point-of-Care Test That Measures COVID-19 Neutralizing Antibodies

by IR Team | Jan 11, 2021 | Press Release

SAN DIEGO, January 11, 2021 — AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announced today that it has released a preprint of its...

AXIM® Biotechnologies Completes Successful Covid-19 Live Virus Test and Files Amended EUA for Portable 10 Minute Rapid Diagnostic Test for Neutralizing Antibodies

by IR Team | Dec 15, 2020 | Press Release

SAN DIEGO – December 15, 2020 – AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announced today that it has filed an amended Emergency Use...

AXIM® Biotechnologies to Present at the 13th Annual LD Micro Main Event Investor Conference on Monday, December 14

by IR Team | Dec 14, 2020 | Press Release

SAN DIEGO – December 14, 2020 – AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announced today that the Company’s CEO John W. Huemoeller...

AXIM® Biotechnologies Develops ELISA-Based Neutralizing Antibody Diagnostic Test for COVID-19 and Applies for Patent; Company’s Fourth COVID-19 Test-Focused Patent Application

by IR Team | Dec 3, 2020 | Press Release

SAN DIEGO, December 3, 2020 — AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or the “Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announced today the development and patent filing for...

AXIM® Biotechnologies Applauds Vaccine Producers, Highlights Need for Rapid Antibody Testing to Ensure Immunity

by IR Team | Nov 10, 2020 | Press Release

SAN DIEGO, Nov. 10, 2020 (GLOBE NEWSWIRE) — AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 research, applauds the recent announcement from...